Tirzepatide Meets Immunology
Lilly reported one-year phase 3b results combining tirzepatide with ixekizumab in adults with psoriatic disease and obesity.
A note from the press room
What changed—and what did not
No new indication or label change was announced. Tirzepatide remains approved for its existing indications; this combination strategy is not established here as a newly approved use.
The study record
Controlled human evidence: Lilly reported 52-week results from two randomized, multicenter, assessor-blinded, open-label phase 3b studies. Combination groups had higher composite disease-and-weight outcomes than ixekizumab alone. Week-52 analyses were prespecified exploratory objectives without multiplicity control.
What happened in people
TOGETHER-PsO enrolled 274 adults and TOGETHER-PsA enrolled 271. Lilly reported no new safety concerns; common events in combination groups included gastrointestinal symptoms, injection-site reactions, dizziness, and headache. Full peer-reviewed publication was pending.
The company ledger
Confirmed disclosure: Eli Lilly and Company (developer and license holder; NYSE: LLY) released the results August 31. This edition does not assign a share-price move to the announcement without verified event-specific evidence.
No investment recommendation is made.
Classification check
Tirzepatide remains a New Disciple. The trials broaden the human record around concomitant use but do not create a new canon classification.
What evidence comes next
Peer-reviewed reports and regulator-reviewed labeling would carry more weight than a company release.
Questions to explore
Combination trials: separating weight loss, inflammation, and exploratory endpoints
- Study or disclosure design
- What the headline leaves out
- Regulatory and commercial context
- Questions the next evidence must answer
Primary and authoritative sources
Conflicts: the principal source is a disclosure from the product developer or sponsor. No sponsor paid for classification or coverage.